4/21/04

Please type a plus sign (+) inside this box Pro/sB/08A (10-Approved for use through 10/31/99. OMB 0651-01 Patent and Trademark Office: U.S. DEPARTMENT OF COMMER Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number								
(	Substitu	de for form 1449A/PT	· · · · · · · · · · · · · · · · · · ·		Complete If Known			
					Not Yet Known	1		
	INF	ORMATION	l DIS	SCLOSURE	Filing Date	Herewith		
1	STA	TEMENT E	BY A	PPLICANT	First Named Inventor	WEICHERT		
	(use as many sheets as necessary)				Group Art Unit	1624		
					Examiner Name	T. TRUONG		
- (	Sheet	1	of	2	Attorney Docket Number	DEAV2003/0029 - US - NP		

				U.S. PATENT DOC	JMENTS	class/subclass	
Examiner	Cite	U.S. Patent	Document	Name of Patentee or Applicant	Date of Publication of	Rooms Cohomos tines,	
Initials'	No.1	Number	Kind Code <sup>3</sup> ( <i>II known</i> )	of Cited Document	Cited Document MM-DD-YYYY	- Passages or Relevant - Passages Appear	
		10/146671		GARVEY, et al.	05-16-2002		
	./_	6,617,359		STROBEL	09-09-2003	514/617	
		10/73160		STROBEL	02-13-2002		
		10/73203		STROBEL	02-13-2002		
		10/73307		STROBEL	02-13-2002		
						· · · · · · · · · · · · · · · · · · ·	
		<u> </u>					
<del>-  </del>		<del>                                     </del>			<del></del>		
<del></del>			<del></del>		+		
				****	<del>                                     </del>	•	
$\neg \uparrow$						<del></del>	
İ							
					1 -		
1							

				FOR	EIGN PATENT DOCUMEN	TS		
Examiner Initials	Cite No.1	Office	Foreign Patent Do Number <sup>4</sup>	cument Kind Code <sup>s</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Te
TM		wo	WO 00/03746		LIAO	01-27-2000		T
TVI	_	wo	WO 99/47153		LIAO	09-23-1999		
		$\vdash$		-				$\bot$
					•			İ
								$\vdash$
						<del> </del>		╁╴

Examiner	011	Date	111
Signature	- Man	Considered	5/5/05

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-latter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the sartal number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

•	
Please type a plus sign (+) inside this box ->	_
Pigara ivog a cius sion (+) inside inis dox	
, 10000 1, pro 0 proc 0 graf, 7	

PTO/SB/088 (10-95)
Please type a plus sign (+) Inside this box 
Approved for use through 10/31/99, OMB 0851-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitu	te for form 1449B/P1	ro		Complete If Known			
				Application Number	Not Yet Known Herewith		
INFO	DRMATIO	ND	ISCLOSURE	Filing Date			
STA	TEMENT	RY	APPLICANT	First Named Inventor	WEICHERT		
OTATEMENT DI ALL EIGANI				Group Art Unit	1624		
	(use as many	sheet	s as necessary)	Examiner Name	T. TRUONE		
Sheet	2	of	2	Attorney Docket Number	DEAV2003/0029 - US - NP		

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initlals	Cite No.1	Include name of the euthor (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	r
71/	/	DRIVER, et al., A Second-Generation Catalyst for Aryl Halide Amination: Mixed Secondary Amines from Aryl Halides and Primary Amines Catalyzed by (OPPF)PdCl2, J. AMer. Chem Soc.; 118; 1996; pp.7217-7218.	
	/	ENDRES, et al., Stroke Protection By 3-Hydroxy-3-Methylglutaryl (HMG) - CoA Reductase Inhibitors Medicated By Endothelial Nitric Oxide Synthase, Proc. Natl. Acad. Sci. USA, 95 (1998) 8880-8885,	
	1	LI Hulge et al., Activation of Protein Kinase C(alpha) and/or (epsilon) Enhances Transciption of the Human Endothelial Nitric Oxide Synthase Gene, Mol. Pharmacol., 1998, Vol. 53, pp 630-637	
	V	MARTIN-SANTAMARIA, et al., Synthesis and Stereochemistry of 11,11a-Dihydro Derivatives of (4S)-2,4-Dimethyl-2,4dihydro-1H-pyrazino[2,1-b]quinazoline-3,6-diones. A New Transannular Rearrangement Proposal., J. Org.Chem.; 64; 1999; pp.7233-7235.	
	v	MOROI, et al., Interaction of Genetic Deficiency of Endothelial Nitric Oxide, Gender, and Pregnancy in Vascular Response to Injury in Mice, J. Clin. Invest., 101 (1898) 1225-1232	
	./	NAKAYAMA Masafumi et al., T-788>C Mutation in the 5'-Flanking Region of the Endothelial Ntric Oxide Synthase Gene Is Associated with Coronary Spasm, Clinical Investigation and Reports, Circulation 99, 1999, pp 2864-2870	
	/	SESSA, et al., Chronic Exercise In Dogs Increases Coronary Vascular Nitric Oxide Production And Endothelial Cell Nitric Oxide Synthase Gene Expression, Circ. Research 74 (1994) 349-353	
	- 1	VARENNE, et al., Percutaneous Gene Therapy Using Recombinant Adenoviruses Encoding Human Herpes Simplex Virus Thymidine Kinase, Human PAI-1, and Human NOS3 in Balloon-Injured Porcine Coronary Arteries, Hum. Gene Ther. 11 (2000) 1329-1339 ,	
WT		VOJKOVSKY, et al., Solid-Phase Synthesis of Heterocycles Containing an 1-Acyl-3-oxopiperazine Skeleton, J. Org. Chem.; 63; 1998; pp. 3162-3163.	

Examiner	110	Date	111-
Signature	Mom	Considered	515/05
0.3.12.5.0		COMPIGNATION	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

2.09.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.